Compare VVX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | ADMA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2014 | 2012 |
| Metric | VVX | ADMA |
|---|---|---|
| Price | $86.55 | $8.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $69.88 | $25.67 |
| AVG Volume (30 Days) | 470.9K | ★ 3.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | N/A |
| EPS | ★ 0.60 | 0.19 |
| Revenue | ★ $4,480,038,000.00 | $42,219,783.00 |
| Revenue This Year | $7.81 | $27.46 |
| Revenue Next Year | $5.84 | $22.11 |
| P/E Ratio | $144.25 | ★ $44.00 |
| Revenue Growth | 3.65 | ★ 43.85 |
| 52 Week Low | $46.27 | $7.21 |
| 52 Week High | $91.80 | $20.46 |
| Indicator | VVX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 45.63 |
| Support Level | $66.71 | $7.38 |
| Resistance Level | N/A | $8.90 |
| Average True Range (ATR) | 2.90 | 0.33 |
| MACD | -0.13 | 0.14 |
| Stochastic Oscillator | 38.66 | 59.52 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.